EMA recommends rejecting Anavex’s blarcamesin for the treatment of Alzheimer’s disease

ahsan65@gmail.com2 weeks ago

0 2 Less than a minute

The European Medicines Agency recommends that Anavex Life Sciences (AVXL) the application for marketing authorization for blarcamesin, a treatment against Alzheimer’s disease, is rejected.
The agency said the main study submitted “failed to demonstrate the efficacy and safety of Blarcamesin Anavex in patients with early onset syndrome.”